ProQR Therapeutics (PRQR) Current Deferred Revenue (2021 - 2025)

ProQR Therapeutics' Current Deferred Revenue history spans 4 years, with the latest figure at $23.4 million for Q4 2024.

  • For Q4 2024, Current Deferred Revenue rose 5.95% year-over-year to $23.4 million; the TTM value through Dec 2024 reached $23.4 million, up 5.95%, while the annual FY2024 figure was $23.7 million, 6.74% up from the prior year.
  • Current Deferred Revenue for Q4 2024 was $23.4 million at ProQR Therapeutics, up from $22.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $23.4 million in Q4 2024 and bottomed at $5.8 million in Q4 2022.
  • The 4-year median for Current Deferred Revenue is $14.0 million (2021), against an average of $14.3 million.
  • The largest annual shift saw Current Deferred Revenue decreased 1.64% in 2022 before it skyrocketed 284.54% in 2023.
  • A 4-year view of Current Deferred Revenue shows it stood at $5.9 million in 2021, then fell by 1.64% to $5.8 million in 2022, then soared by 284.54% to $22.1 million in 2023, then rose by 5.95% to $23.4 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Current Deferred Revenue are $23.4 million (Q4 2024), $22.1 million (Q4 2023), and $5.8 million (Q4 2022).